期刊文献+

吉米沙星关键中间体4-氨甲基吡咯烷-3-酮-O-甲基肟二盐酸盐的合成方法改进 被引量:5

Improved synthesis of a gemifloxacin intermediate 4-(aminomethyl)pyrrolidin-3-one-O-methyloxime dihydrochloride
原文传递
导出
摘要 目的合成抗菌药吉米沙星关键中间体4-氨甲基吡咯烷-3-酮-O-甲基肟二盐酸盐。方法以甘氨酸乙酯盐酸盐为原料,依次经加成、Boc保护氨基、Dieckmann环化、NaBH4还原羰基、LiAlH4还原氰基、Boc保护氨甲基、氧化、肟化、脱Boc保护等9步反应制得目标化合物。结果与结论合成的目标化合物经1H-NMR和MS谱确证结构,总收率由25.8%提高至39.6%。该合成工艺省去了文献方法中对中间体4和6的柱色谱分离,不经纯化直接用于下步反应,简化了操作步骤。 Aim To synthesize a gemifloxacin intermediate,4-(aminomethyl) pyrrolidin-3-one-O-methyloxime dihydrochloride. Methods Commercially available glycine ethyl ester hydrochloride was used as starting material to give the target compound via addition, protection with Boc, Dieckmann cyclization, reduction with NaBH4 and LiAlH4, protection, oxidation, oximation and deprotection. Results and conclusion The target compound was prepared in 39.6% overall yield and its structure was identified by ^1H-NMR and MS.
出处 《中国药物化学杂志》 CAS CSCD 2009年第2期109-111,共3页 Chinese Journal of Medicinal Chemistry
关键词 喹诺酮 吉米沙星 中间体 工艺改进 quinolone gemifloxacin intermediate process improvement
  • 相关文献

参考文献4

  • 1陈胜昔,郭惠元.新的广谱、高效喹诺酮类抗菌药gemifloxacin[J].国外医药(抗生素分册),2002,23(6):279-283. 被引量:11
  • 2HONG C Y, KIM Y K, CHANG J H, et al. Novel fluoroquinolone antibacterial agents containing oxime- substituted ( aminomethyl ) pyrrolidines: synthesis and antibacterial activity of 7- ( 4- (aminomethyl) -3- ( me- thoxyimino ) pyrrolidin-1-yl ) -1-cyclopropyl-6-fluoro- 4-oxo-1,4-dihydro [ 1,8 ] naphthyridine-3-carboxylic acid( LB20304 ) [ J ]. J IVied Chem, 1997,40 ( 22 ) : 3584 - 3593.
  • 3洪昌容,金永宽,蒋在赫,等.有7-(4-氨基甲基.3-肟)吡咯烷取代基的新喹啉羧酸衍生物和其制法:中国,1114959[P].1993-07-14.
  • 4PARIKH J R,DOERING W V E. Sulfurtrioxide in the oxidation of alcohols by dimethyl sulfoxide[ J]. J Am Chem Soc, 1967,89(21 ) :5505 - 5507.

二级参考文献24

  • 1[1]Morrissey I, George JT. Purification of pneumococcal type Ⅱ topoisomerases and inhibition by gemifloxacin and other quinolones. [J]. JAntimicrob Chemother, 2000, 45(Suppl S1):101
  • 2[2]Hardy D, Amsterdam D, Mandell LA, et al. Comparative in vitro activities of ciprofloxacin, gemifloxacin, grepafloxacin, moxifloxacin, ofloxacin, sparfloxacin, trovafloxacin, and other antimicrobial agents against bloodstream isolates of gram-positive cocci. [J]. Antimicrob Agents Chemother, 2000, 44(2):802
  • 3[3]Cormican MG, Jones RN. Antimicrobial activity and spectrum of LB20304, a novel fluoronaphyridone. [J]. Antimicrob Agents Chemother, 1997, 41(1): 200
  • 4[4]Goldstein EJC, Citron DM, Warren Y, et al. In vitro activity of gemifloxacin (SB 265805) against anaerobes. [J]. Anfimicrob Agents Chemother, 1999, 43(9): 2231-2235
  • 5[5]Dubois J, St-Pierre C. Comparative in vitro potency and post-antibiotic effect of gemifloxacin against Legionella spp. [J]. J Antimicrob Chemother, 2000, 45 (suppl. S1): 41
  • 6[6]Roblin PM, Reznik T, Kutlin A, et al. In vitro activities of gemifloxacin (SB 265805, LB20304) against recent chnical isolates of Chlamydia pneumoniae. [J]. Antimicrob Agents Chemother, 1999, 43(11):2806
  • 7[7]Oh JI, Paek KS, Ahn MJ, et al. In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone. [J]. Antimicrob Agents Chemother, 1996, 40(6): 156 4
  • 8[8]Berry V, Page R, Satterfield J, et al. Comparative in vivo activity of gemifloxacin in a rat model of respiratory tract infection. [J]. J Antimicrob Chemother, 2000,45(Suppl S1):79
  • 9[9]Berry V, Page R, Satterfield J, et al. Comparative efficacy of gemifloxacinin experimental modes of pyelonephritis and wound infection. [J].J Antimicrob chemother, 2000,45(suppl s1): 87
  • 10[10]Dubois J, St-Pierre C. Comparative in vitro activity and post-antibiot ic effect of gemifloxacin against Legionella spp. [ J]. J Antimicrob Chemother, 2000, 45 (Suppl S1): 41

共引文献10

同被引文献29

引证文献5

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部